精油與壓力皮膚 / Essential oils and stress-related skin
As I mentioned in our last blog that psychodermatorology could be more efficient and effective in addressing stress-related skin problems, we believe essential oils (EOs) is one of them as they work on both skin and emotion.
For psychological issue, EOs are well-known in addressing issues related to mental strain, stress, anxiety, nervous tension, depression and sadness, etc. Thanks to some of their constituents which interact with the nervous system. For example, most citrus essential oil are high in monoterpenes, which are stimulating and uplifting; ester and sesquiterpenes are calming and sedative, such as Clary Sage, Lavender and Vetiver.
For skin problem, some EOs are antiseptic, anti-bacterial, anti-viral and anti-fungal. Some also helps in skin regeneration, complexion toning, scar lightening, skin rashes and allergy, etc. For example, rose oil is famous in skin rejuvenation, while tea tree oil is good in treating acnes problem.
More importantly, some EOs can deal with both psychological and skin issues at the same time. This includes rose, palmarosa, lavender, geranium, sandalwood, neroli and petitgrain, etc. It is interesting to note that there are in-vitro and in-vivo studies on lavender, rose, sandalwood and copaiba in helping stress-related skin problem through addressing psychological stress, cortisol production and inflammation, hyper-proliferation or abnormal differentiation of keratinocytes, or skin barrier dysfunction.
Relaxing effect of rose oil on humans https://pubmed.ncbi.nlm.nih.gov/19370942/
Sandalwood oil downregulates skin inflammation through 11β-HSD1 activation in keratinocytes. Journal of Dermatological Science, 84(1), e134.
Effect of “rose essential oil” inhalation on stress- induced skin-barrier disruption in rats and humans. http:// doi.org/10.1093/chemse/bjr108
GC-MS profiling of the phytochemical constituents of the oleoresin from Copaifera langsdorffii Desf. and a preliminary in vivo evaluation of its antipsoriatic effect. http://doi.org/10.1016/j.ijpharm.2012.08.021